In vitro potency evaluations of various piperacillin/tazobactam generic products compared to the contemporary branded (Zosyn®, Wyeth) formulation [Diagnostic Microbiology and Infectious Disease 61, 76-79, 2008] (DOI:10.1016/j.diagmicrobio.2007.12.010);In vitro potency evaluations of various piperacillin/tazobactam generic products compared with the contemporary branded (Zosyn®, Wyeth) formulation

Diagnostic Microbiology and Infectious Disease

Volumn 61, Issue 1, 2008, Pages 76-79

  Jones, Ronald N ^a,b   Fritsche, Thomas R ^a   Moet, Gary J ^a  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Activity in vitro; Branded agents; Generics; Piperacillin tazobactam

Indexed keywords

GENERIC DRUG; PIPERACILLIN PLUS TAZOBACTAM; PIPTAMATE; PIPTAZ; PISUTAM; PRIZMAI; TAPIMYCIN; TAZIDRON; TAZOREX; TAZOTUM; UNCLASSIFIED DRUG; VIGOCID; ZOBACTIN; ZOPERCIN;

ANTIMICROBIAL ACTIVITY; ARTICLE; BROTH DILUTION; COMPARATIVE STUDY; CONTROLLED STUDY; DISK DIFFUSION; DRUG FORMULATION; DRUG POTENCY; ESCHERICHIA COLI; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 41949084172     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2008.04.011     Document Type: Erratum

References (13)

1. CLSI. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard-7th edition (2006), CLSI, (M7-A7). Wayne, PA
2. CLSI. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard-9th edition (2006), CLSI, (M2-A9). Wayne, PA
3. CLSI. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, 17th Informational Supplement (2007), CLSI, (M100-S17). Wayne, PA
4. Jones R.N., and Barry A.L. Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830). Diagn. Microbiol. Infect. Dis. 12 (1989) 495-510
5. Kuck N.A., Petersen P.J., Weiss W.J., Jacobus N.V., Testa R.T., and Tally F.P. Synergistic activity of piperacillin: YTR-830H combinations in vitro and in vivo. J. Chemother. 1 (1989) 105-106
6. Lambert P.A., and Conway B.R. Pharmaceutical quality of ceftriaxone generic drug products compared with Rocephin. J. Chemother. 15 (2003) 357-368
7. Package Insert (2007). Zosyn® (available at www.zosyn.com; accessed February 2007).
8. Pasqualotto A.C., and Denning D.W. Generic substitution of itraconazole resulting in sub-therapeutic levels and resistance. Int. J. Antimicrob. Agents 30 (2007) 93-94
9. Rodriguez C.A., Zuluaga A.F., Salazar B.E., Agudelo M., and Vesga O. Experimental comparison of 11 generic products (GP) of oxacillin (OXA) with the original compound (OC) in terms of concentration of active principle (CAP), in vitro activity, and in vivo efficacy, using the neutropenic murine thigh infection model (NMTIM), Abstr. A-1305. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, D.C. (2004) 28
10. Schito G.C., and Keenan M.H. Predicting the clinical efficacy of generic formulations of ceftriaxone. J. Chemother. 17 Suppl 2 (2005) 33-40
11. Wetterich U., and Mutschler E. Quality of cefotaxime sodium preparations. Arzneimittelforschung 45 (1995) 74-80
12. Ye Y., Lee J., Chen Y., Lin S., and Chien S. A comparative study of the clinical efficacy of two piperacillin/tazobactam products, Poster 27. Annual Conference of Taiwan Society of Health System Pharmacists, Taiwan (2006)
13. Zuluaga A.F., Salazar B.E., Loaiza S.A., Agudelo M., and Vesga O. Therapeutic equivalence (TE) with the original compound (OC) of 8 genetic products (GP) of ampicillin (AMP) determined in the neutropenic murine thigh infection model (NMTIM), Abstr. E-2033. 44th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, D.C (2004)